Dongliang Bian

机构：Tongji University, Shanghai Pulmonary Hospital, Zhejiang Medicine (China) · ORCID：0000-0002-5779-2593

发表论文 54 篇 · 总被引 975 次 · h-index 14

代表论文

• Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer (2024 · Nature Genetics · 被引 146)
• Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study (2024 · Signal Transduction and Targeted Therapy · 被引 35)
• Short-term intra- and peri-tumoral spatiotemporal CT radiomics for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer (2025 · European Radiology · 被引 16)
• Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial (2025 · Nature Communications · 被引 15)
• Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial (2025 · Nature Communications · 被引 15)
• Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial (2025 · BMC Medicine · 被引 6)